Flash-spelare saknas/Javascript är inte aktiverat
Board
 |
Bengt Å Johansson, MSc - Chairman
Bengt has long experience from Astra and AstraZeneca, from commercialisation, strategic development and transaction of products and projects. |
 |
Gunvor Ekman-Ordeberg, MD, PhD
Professor of Obstetrics and Gynecology at Karolinska Institutet. Leader of a research group of 15 associates specializing in clinical development and experimental research in obstetrics and gynecology.
|
 |
Hans-Peter Ekre, BSc
Research studies in Immunlogy. Investment Manager of Karolinska Development. 25 years in senior positions in drug discovery at AstraZeneca and Kabi Pharmacia. |
 |
Tore Mellstrand, MScPharm, PhD
30 years experience in academic research and the pharmaceutical industry. Leading positions in clinical development and marketing at Janssen, Kabi and Pharmacia in Sweden and internationally.
|
 |
Eva Sjökvist Saers, MScPharm, PhD
Academic research and long experience in the pharmaceutical industry. Leading positions in drug development at AstraZeneca. CEO at Apotekets Produktion & Laboratorier and chairman at the Swedish Academy of Pharmaceutical Sciences.
|
NEWS
2010-08-30
Dilafor announces the selected INN for DF02, sevuparin
2010-08-18
Dilafor initiates partnering process for tafoxiparin
2009-12-17
Dilafor adds important capabilities to the board
Copyright © 2001-2010. All rights reserved.
